Day One Biopharmaceuticals Inc

NASDAQ DAWN

Download Data

Day One Biopharmaceuticals Inc Debt to Asset Ratio 1 year YoY Change (%) for the Trailing 12 Months (TTM) ending September 20, 2024

Day One Biopharmaceuticals Inc Debt to Asset Ratio 1 year YoY Change (%) is NA for the Trailing 12 Months (TTM) ending September 20, 2024. The debt to asset ratio measures the proportion of a company's total assets that are financed by debt. It is calculated by dividing total debt by total assets. This ratio indicates the extent to which a company relies on debt financing to support its asset base. A higher ratio suggests a higher level of leverage and potential financial risk. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.
NASDAQ: DAWN

Day One Biopharmaceuticals Inc

CEO Dr. Jeremy Bender M.B.A., Ph.D.
IPO Date May 27, 2021
Location United States
Headquarters 395 Oyster Point Boulevard, South San Francisco, CA, United States, 94080
Employees 174
Sector Healthcare
Industry Biotechnology
Description

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.

Similar companies

ABOS

Acumen Pharmaceuticals Inc

NA

NA

ELDN

Eledon Pharmaceuticals Inc

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email